Medical condition
Copd
Copd is a medical condition tracked by NovaPharmaNews across 12 associated drugs and ongoing industry coverage. Explore approved and pipeline therapies, regulatory status, and the latest developments.
Associated drugs & therapies
- salmeterol (SEFFALAIR SPIROMAX) Respiratory system (R03)
- salmeterol xinafoate (AIREXAR SPIROMAX) Respiratory system (R03)
- roflumilast (DAXAS) Respiratory system (R03)
- dupilumab (DUPIXENT) Dermatologicals (D11)
- budesonide (BUDENOFALK) Alimentary tract and metabolism (A07)
- umeclidinium bromide (ANORO ELLIPTA (PREVIOUSLY ANORO)) Respiratory system (R03)
- fluticasone furoate (ARNUITY ELLIPTA) Respiratory system (R03)
- ensifentrine (OHTUVAYRE) Respiratory system (R03)
- aclidinium bromide (BRETARIS GENUAIR) Respiratory system (R03)
- umeclidinium (INCRUSE ELLIPTA) Respiratory system (R03)
- glycopyrronium bromide (ENUREV BREEZHALER) Respiratory system (R03)
- glycopyrronium (AXHIDROX) Respiratory system (R03)
Latest Copd news
FDA approves Dupixent for COPD with eosinophilic phenotype
The FDA has approved Dupixent as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. The decision gives Regeneron and Sanofi a new regulatory catalyst to track for commercial and investor implications.
Tozorakimab Meets Primary Endpoint in Phase III COPD Trial, Shows Significant Reduction in Exacerbations
First-in-class tozorakimab demonstrates statistically significant reduction in COPD exacerbations across all patient populations in pivotal Phase III MIRANDA trial.
Nuance Pharma's Ohtuvayre Shows Improved Lung Function in Chinese COPD Patients - ENHANCE-CHINA Phase 3 Results Published
Nuance Pharma announces CHEST journal publication of Phase 3 ENHANCE-CHINA trial showing Ohtuvayre (ensifentrine) improved lung function in Chinese COPD patients.
FDA Approves Inhalex: New COPD Maintenance Treatment by NovaPharm
Inhalex, the latest COPD maintenance treatment by NovaPharm, has received FDA approval, promising enhanced management of chronic obstructive pulmonary disease.